214 related articles for article (PubMed ID: 27974211)
1. Dual Shp2 and Pten Deficiencies Promote Non-alcoholic Steatohepatitis and Genesis of Liver Tumor-Initiating Cells.
Luo X; Liao R; Hanley KL; Zhu HH; Malo KN; Hernandez C; Wei X; Varki NM; Alderson N; Chu C; Li S; Fan J; Loomba R; Qiu SJ; Feng GS
Cell Rep; 2016 Dec; 17(11):2979-2993. PubMed ID: 27974211
[TBL] [Abstract][Full Text] [Related]
2. Shp2 deletion in hepatocytes suppresses hepatocarcinogenesis driven by oncogenic β-Catenin, PIK3CA and MET.
Liu JJ; Li Y; Chen WS; Liang Y; Wang G; Zong M; Kaneko K; Xu R; Karin M; Feng GS
J Hepatol; 2018 Jul; 69(1):79-88. PubMed ID: 29505847
[TBL] [Abstract][Full Text] [Related]
3. Single-cell transcriptomics reveals opposing roles of Shp2 in Myc-driven liver tumor cells and microenvironment.
Chen WS; Liang Y; Zong M; Liu JJ; Kaneko K; Hanley KL; Zhang K; Feng GS
Cell Rep; 2021 Nov; 37(6):109974. PubMed ID: 34758313
[TBL] [Abstract][Full Text] [Related]
4. Dual faces of SH2-containing protein-tyrosine phosphatase Shp2/PTPN11 in tumorigenesis.
Li S; Hsu DD; Wang H; Feng GS
Front Med; 2012 Sep; 6(3):275-9. PubMed ID: 22869052
[TBL] [Abstract][Full Text] [Related]
5. [Tumor suppressor gene PTEN and non-alcoholic steatohepatitis (NASH)].
Sato W; Horie Y; Watanabe S; Suzuki A
Nihon Rinsho; 2005 Aug; 63(8):1475-83. PubMed ID: 16101243
[TBL] [Abstract][Full Text] [Related]
6. Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis.
Bard-Chapeau EA; Li S; Ding J; Zhang SS; Zhu HH; Princen F; Fang DD; Han T; Bailly-Maitre B; Poli V; Varki NM; Wang H; Feng GS
Cancer Cell; 2011 May; 19(5):629-39. PubMed ID: 21575863
[TBL] [Abstract][Full Text] [Related]
7. Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play.
Charrez B; Qiao L; Hebbard L
World J Gastroenterol; 2016 Feb; 22(8):2494-502. PubMed ID: 26937137
[TBL] [Abstract][Full Text] [Related]
8. Shp2 and Pten have antagonistic roles in myeloproliferation but cooperate to promote erythropoiesis in mammals.
Zhu HH; Luo X; Zhang K; Cui J; Zhao H; Ji Z; Zhou Z; Yao J; Zeng L; Ji K; Gao WQ; Zhang ZY; Feng GS
Proc Natl Acad Sci U S A; 2015 Oct; 112(43):13342-7. PubMed ID: 26460004
[TBL] [Abstract][Full Text] [Related]
9. Depletion of S100A4
Jiao J; González Á; Stevenson HL; Gagea M; Sugimoto H; Kalluri R; Beretta L
Exp Mol Med; 2018 Jan; 50(1):e422. PubMed ID: 29303514
[TBL] [Abstract][Full Text] [Related]
10. Non-alcoholic steatohepatitis and hepatocellular carcinoma: lessons from hepatocyte-specific phosphatase and tensin homolog (PTEN)-deficient mice.
Watanabe S; Horie Y; Kataoka E; Sato W; Dohmen T; Ohshima S; Goto T; Suzuki A
J Gastroenterol Hepatol; 2007 Jun; 22 Suppl 1():S96-S100. PubMed ID: 17567478
[TBL] [Abstract][Full Text] [Related]
11. Molecular profiling of nonalcoholic fatty liver disease-associated hepatocellular carcinoma using SB transposon mutagenesis.
Kodama T; Yi J; Newberg JY; Tien JC; Wu H; Finegold MJ; Kodama M; Wei Z; Tamura T; Takehara T; Johnson RL; Jenkins NA; Copeland NG
Proc Natl Acad Sci U S A; 2018 Oct; 115(44):E10417-E10426. PubMed ID: 30327349
[TBL] [Abstract][Full Text] [Related]
12. MUTYH is associated with hepatocarcinogenesis in a non-alcoholic steatohepatitis mouse model.
Sakamoto H; Miyanishi K; Tanaka S; Ito R; Hamaguchi K; Sakurada A; Sato M; Kubo T; Osuga T; Murase K; Takada K; Nakabeppu Y; Kobune M; Kato J
Sci Rep; 2021 Feb; 11(1):3599. PubMed ID: 33574380
[TBL] [Abstract][Full Text] [Related]
13. PTEN in non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and cancer.
Peyrou M; Bourgoin L; Foti M
Dig Dis; 2010; 28(1):236-46. PubMed ID: 20460918
[TBL] [Abstract][Full Text] [Related]
14. Mouse models for investigating the underlying mechanisms of nonalcoholic steatohepatitis-derived hepatocellular carcinoma.
Takakura K; Oikawa T; Tomita Y; Mizuno Y; Nakano M; Saeki C; Torisu Y; Saruta M
World J Gastroenterol; 2018 May; 24(18):1989-1994. PubMed ID: 29760542
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice.
Tessitore A; Cicciarelli G; Del Vecchio F; Gaggiano A; Verzella D; Fischietti M; Mastroiaco V; Vetuschi A; Sferra R; Barnabei R; Capece D; Zazzeroni F; Alesse E
BMC Cancer; 2016 Jan; 16():3. PubMed ID: 26728044
[TBL] [Abstract][Full Text] [Related]
16. Different roles of FAT10, FOXO1, and ADRA2A in hepatocellular carcinoma tumorigenesis in patients with alcoholic steatohepatitis (ASH) vs non-alcoholic steatohepatitis (NASH).
Jia Y; French B; Tillman B; French S
Exp Mol Pathol; 2018 Aug; 105(1):144-149. PubMed ID: 30009772
[TBL] [Abstract][Full Text] [Related]
17. Regular exercise decreases liver tumors development in hepatocyte-specific PTEN-deficient mice independently of steatosis.
Piguet AC; Saran U; Simillion C; Keller I; Terracciano L; Reeves HL; Dufour JF
J Hepatol; 2015 Jun; 62(6):1296-303. PubMed ID: 25623824
[TBL] [Abstract][Full Text] [Related]
18. Wnt/β-catenin activation and macrophage induction during liver cancer development following steatosis.
Debebe A; Medina V; Chen CY; Mahajan IM; Jia C; Fu D; He L; Zeng N; Stiles BW; Chen CL; Wang M; Aggarwal KR; Peng Z; Huang J; Chen J; Li M; Dong T; Atkins S; Borok Z; Yuan W; Machida K; Ju C; Kahn M; Johnson D; Stiles BL
Oncogene; 2017 Oct; 36(43):6020-6029. PubMed ID: 28671671
[TBL] [Abstract][Full Text] [Related]
19. Eicosapentaenoic acid ameliorates steatohepatitis and hepatocellular carcinoma in hepatocyte-specific Pten-deficient mice.
Ishii H; Horie Y; Ohshima S; Anezaki Y; Kinoshita N; Dohmen T; Kataoka E; Sato W; Goto T; Sasaki J; Sasaki T; Watanabe S; Suzuki A; Ohnishi H
J Hepatol; 2009 Mar; 50(3):562-71. PubMed ID: 19162361
[TBL] [Abstract][Full Text] [Related]
20. Lipid-lowering agents inhibit hepatic steatosis in a non-alcoholic steatohepatitis-derived hepatocellular carcinoma mouse model.
Orime K; Shirakawa J; Togashi Y; Tajima K; Inoue H; Nagashima Y; Terauchi Y
Eur J Pharmacol; 2016 Feb; 772():22-32. PubMed ID: 26724391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
